Inactivated influenza vaccine timing

The inactivated influenza vaccine preparations generally contain 45 meg antigen in 15-mcg trivalent units per 0.5 mL and are administered by IM injection. Split-virus vaccine must be used for children from 6 months to 12 years of age. Children 6 to 35 months old receive 0.25 mL of split-virus vaccine. Two doses of vaccine administered at least 1 month apart are necessary for all children younger than 9 years of age who are receiving the vaccine for the first time. Split-virus vaccine is less reactogenic than whole-virus vaccine, particnlarly in children. Whole- or split-virus vaccine can be administered to individuals older than 12 years of age. However, whole-vims vaccines are not available in the United States. ... 

Observational studies In October 2003 the Advisory Committee on Immunization Practices (ACIP) recommended influenza immunization for all children aged 6-23 months [30 ]. The safety of this recommendation has been evaluated using the Vaccine Adverse Event Reporting System (VAERS) to study serious adverse events reported between 1 July 2003 and 30 June 2006 in children aged 6-23 months who had been given trivalent inactivated influenza vaccine. There were 104 serious adverse events at a median time after immunization of 1 day. The two most common serious adverse events were fever (52 reports) and seizures (35 reports). Causality assessment suggested that none was definitely related to influenza vaccine. No new or unexpected concerns were identified. 

Influenza Inactivated virus or viral components Intramuscular One dose (children si 2 years of age should receive split virus vaccine only children < 9 who are receiving influenza vaccine for the first time should receive two doses administered at least 1 month apart) Yearly with current vaccine 1. Adults 50 years of age 2. Person s with high risk condit ions (eg, asthm a) 3. Health care worke rs and others in contac t with high-risk groups 4. Reside nts of nursin g homes and other reside ntial chroni c care faciliti es... 

Appropriate immunizations should be a primary consideration in the prevention of infections in HSCT recipients. Immunizations against common bacterial and viral pathogens are timed to avoid periods of severe immunosuppression following HSCT when the protective response to vaccination potentially would be decreased. Current recommendations for immunization of HSCT patients include three doses each of diphtheria-pertussis-tetanus or diphtheria-tetanus, inactivated polio, conjugated H. influenzae type b, and hepatitis B vaccines at 12, 14, and 24 months after transplantation. The 23-valent pneumococcal vaccine should be administered at 12 and 24 months after HSCT, and the influenza vaccine should be administered prior to HSCT, resumed at least 6 months after transplantation, and con-... 

At its meeting on 3-4 December 2009, the Global Advisory Committee on Vaccine Safety (GACVS) preliminarily reviewed the safety of pandemic A (HlNl) influenza vaccines [29 ]. From 21 September to 2 December 2009, tens of millions of doses of the 2009 HlNl vaccine were administered, providing the basis for this first safety review by the GACVS. Pandemic influenza vaccines include live attenuated vaccines, inactivated unadjuvanted vaccines (split, subunit virion, or whole virion), and inactivated adjuvanted vaccines (split or subunit virion). At the time of the GACVS review, it was estimated that nearly 150 million doses of vaccine had been distributed in many countries around the world. About 30% of those 150 million doses were adjuvanted vaccines. 

---